Bosutinib (Bosulif®)

Assessment Status Rapid Review complete
Drug Bosutinib
Brand Bosulif®
Indication Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Assessment Process
Rapid review commissioned 09/08/2013
Rapid review completed 18/09/2013
Rapid review outcome At the current price a full HTA would be required.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.